SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Natco Pharma jumps after its marketing partner launches 10mg strength for Everolimus Tablets in US market

01 Oct 2021 Evaluate

Natco Pharma is currently trading at Rs. 907.90, up by 16.85 points or 1.89% from its previous closing of Rs. 891.05 on the BSE.

The scrip opened at Rs. 880.35 and has touched a high and low of Rs. 917.95 and Rs. 880.35 respectively. So far 10276 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1188.95 on 24-May-2021 and a 52 week low of Rs. 771.00 on 19-Feb-2021.

Last one week high and low of the scrip stood at Rs. 917.95 and Rs. 871.25 respectively. The current market cap of the company is Rs. 16592.74 crore.

The promoters holding in the company stood at 48.87%, while Institutions and Non-Institutions held 29.94% and 21.19% respectively.

Natco Pharma’s marketing partner Breckenridge Pharmaceutical, Inc., US has launched the 10 mg strength of Everolimus Tablets (generic for Afinitor) in the US market. The U.S. Food and Drug Administration previously granted final approval of this Abbreviated New Drug Application.

According to industry sales data, the 10 mg strength of Afinitor generated annual sales of $392 million during the twelve months ending July 2021. Breckenridge previously launched Everolimus tablets in 2.5 mg, 5 mg and 7.5 mg strengths during the first quarter of 2021 in the US market.

Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.

Natco Pharma Share Price

1118.95 31.25 (2.87%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×